Medplus Health fell 4.8% after Q1 miss; Nomura cut target, citing rising costs and slower revenue growth.

• Nomura maintained “buy” but trimmed target to Rs 1,030, implying 12.1% upside from current levels.
• Q1 EBITDA missed due to elevated employee expenses; FY26–27 estimates cut by 15–22%.
• Despite the drop, stock is still up 5.2% YTD; median analyst target stands at Rs 1,087.5.